on Theranexus (EPA:ALTHX)
THX Pharma successfully completes its €7.8 million capital increase
THX Pharma, specializing in rare neurological diseases, has announced a €7.8 million fundraising round. The operation, aimed at supporting the company's development and financial structure, was a success thanks to shareholder engagement. The issuance of 4,356,804 shares at a price of €1.80 per share saw a subscription rate of 44.3%. In parallel, subscription commitments secured the financing through guarantees provided by various investors.
The funds will support the company's key projects, including the development of TX01 and Batten-1. TX01 is slated for commercialization in 2027, while Batten-1 is expected to reach the market in 2028. In addition, the company is developing an antisense oligonucleotide platform for other rare diseases.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news